The following are published papers and papers in production or ‘in press’ relating to MAOI drugs.

“MAOIs and anesthesia.” Van den Eynde, V., P. K. Gillman and H. Rosenbaum (2022).

“The prescriber’s guide to classic MAO-inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression.” Van den Eynde, V., P. K. Gillman and x. Others (2022). CNS Spectrums: in press

“The Prescriber’s guide to the MAOI diet – Thinking through tyramine troubles.” Van den Eynde, V., P. K. Gillman and B. B. Blackwell (2022). Psychopharm Bull 52(2): 73-116

“Do the classic MAOIs have differential efficacy across depressive subtypes?” Van den Eynde, V., P. K. Gillman, T. Birkenhagen, et al. (2022). ???: in progress

“MAOI or ECT?  Patient preference and joint decision-making in treatment-resistant depression.” Van den Eynde, V. and P. K. Gillman (2022). in press

“Requiem or resurrection: Classic monoamine oxidase inhibitors revisited.” Van den Eynde, V. and P. K. Gillman (2022). European Neuropsychopharmacology 61: 15-16.

“Prepared mind leads to life-saving medical advice.” Gillman, P. and R. R. Ramsay (2021).

“The larger than linear effect of high-dose tyramine on systolic blood pressure – the MAOI diet modified.” Van den Eynde, V. and P. K. Gillman (2020). Int J Psychiatry Clin Pract: Apr 17;11.  doi: 10.1080/13651501.13652020.11743863.

“A critial appraisal of ‘Hypertensive crisis following the administration of tedizolid: possible serotonin syndrome’.” Van den Eynde, V. and P. K. Gillman (2020). Eur J Hosp Pharm 27(1): 52-54.

“Revitalizing monoamine oxidase inhibitors: A call for action.” Gillman, P. K., S. Feinberg and L. Fochtmann (2019). CNS spectrums:

“A reassesment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths.” Gillman, P. K. (2018). J Neural Transm (Vienna) 125(11): 1707-1717.

“”Much ado about nothing”: monoamine oxidase inhibitors, drug interactions, and dietary tyramine.” Gillman, P. K. (2017). CNS Spectr: 1-3.

“Patient Safety and Methylene Blue-Associated Severe Serotonin Toxicity.” Rosenbaum, H. and P. K. Gillman (2016). A&A Case Reports 7(1):

“Fatal methylene blue associated serotonin toxicity.” Top, W. M., P. K. Gillman, C. J. de Langen and A. Kooy (2014). Neth J Med 72(3): 179-181.

“Methylene blue and serotonin reuptake inhibitors – an update.” Gillman, P. K. (2012). Australian and New Zealand College of Anaesthetists Bulletin June: 43

“Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors.” Gillman, P. K. (2011). Journal of Clinical Psychopharmacology 31(1): 66-74.

“CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity.” Gillman, P. K. (2011). Journal of Psychopharmacology 25(3): 429-423.

Finberg, J. and P. Gillman (2011). Pharmacology of MAO-B inhibitors and the cheese reaction. International Review of Neurobiology. M. Youdim and P. Riederer. Burlington, Elsevier Inc. Academic Press. 100: 169-190.

“Methylene Blue and Serotonin Toxicity: Definite Causal Link.” Gillman, P. K. (2010). Psychosomatics 51(5): 448-449.

“Combining antidepressants: Understanding Drug Interactions is the Sine Qua Non.” Gillman, P. K. (2010). Advances in Psychiatric Treatment 16: 76-78.

“Neuroleptic Malignant Syndrome: Mechanisms, Interactions and Causality.” Gillman, P. K. (2010). Movement Disorders 25(12): 1780-1790.

“Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium.” Stanford, S. C., B. J. Stanford and P. K. Gillman (2009). Journal of Psychopharmacology 24(10): 1433-1438.

“Triptans, Serotonin Agonists, and Serotonin Syndrome (Serotonin Toxicity): A Review.” Gillman, P. K. (2009). Headache 50(2): 264-272.

“Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction.” Ramsay, R. R., C. Dunford and P. K. Gillman (2007). Br J Pharmacol 152(6): 946-951.

“Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.” Gillman, P. K. (2007). British Journal of Pharmacology 151(6): 737-748.

“Serotonin Toxicity Associated with the Use of Linezolid: A Review of Postmarketing Data.” Lawrence, K. R., M. Adra and P. K. Gillman (2006). Clinical Infectious Diseases 42: 1578-1583.

“Methylene Blue implicated in potentially fatal serotonin toxicity.” Gillman, P. K. (2006). Anaesthesia 61: 1013-1014.

“Extracting value from case reports: lessons from serotonin toxicity.” Gillman, P. K. (2006). Anaesthesia 61: 419-422.

“A systematic review of the serotonergic effects of mirtazapine: implications for its dual action status.” Gillman, P. K. (2006). Human Psychopharmacology. Clinical and Experimental 21(2): 117-125.

“A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action.” Gillman, P. K. (2006). Biological Psychiatry 59(11): 1046-1051.

“Drug interactions and fluoxetine: a commentary from a clinician’s perspective.” Gillman, P. K. (2005). Ex Op Drug Saf 4: 965-969.

“NMS and ST: chalk and cheese.” Gillman, P. K. (2005). British Medical Journal:

“Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.” Gillman, P. K. (2005). British Journal of Anaesthesia 95(4): 434-441.

Gillman, P. K. and I. M. Whyte (2004). Serotonin syndrome. Adverse Syndromes and Psychiatric Drugs. P. Haddad, S. Dursun and B. Deakin. Oxford, Oxford University Press: 37-49.

“Making sense of serotonin toxicity reports. A comment on Chopra et al.” Gillman, P. K. (2004). World Journal of Biological Psychiatry 5: 166-167.

“The spectrum concept of serotonin toxicity.” Gillman, P. K. (2004). Pain Medicine 5: 231-232.

“Moclobemide and the risk of serotonin toxicity (or serotonin syndrome).” Gillman, P. K. (2004). Central Nervous System Drug Reviews 10: 83-85.

“Mirtazapine: unable to induce serotonin toxicity?” Gillman, P. K. (2003). Clinical Neuropharmacology 26: 288-289.

“Linezolid and serotonin toxicity.” Gillman, P. K. (2003). Clinical Infectious Diseases 37: 1274-1275.

“Amitriptyline: Dual-Action Antidepressant?” Gillman, P. K. (2003). Journal of Clinical Psychiatry 64: 1391

“Relative toxicity of antidepressants.” Gillman, P. K. (1999). Australian and New Zealand Journal of Psychiatry 33: 444

“Commentary: clomipramine too soon after moclobemide.” Gillman, P. K. (1999). Review of Psychiatry 4: 3-5

“The serotonin syndrome and its treatment.” Gillman, P. K. (1999). Journal of Psychopharmacology 13(1): 100-109.

“Serotonin syndrome following SSRI mono-therapy.” Gillman, P. K. and S. Hodgens (1998). Human Psychopharmacology. Clinical and Experimental 13: 525-526

“Serotonin Syndrome: History and Risk.” Gillman, P. K. (1998). Fundamental and Clinical Pharmacology 12(5): 482-491.

“Serotonin syndrome treated with chlorpromazine.” Gillman, P. K. (1997). Journal of Clinical Psychopharmacology 17: 128-129.

“Successful treatment of serotonin syndrome with chlorpromazine.” Gillman, P. K. (1996). Medical Journal of Australia 165: 345

“Possible serotonin syndrome with moclobemide and pethidine.” Gillman, P. K. (1995). Medical Journal of Australia 162: 554

“MAOIs and dangerousness.” Gillman, P. K. (1994). Australian Prescriber 17(2): 29

“Relationships between tryptophan concentrations in human plasma, cerebrospinal fluid and cerebral cortex following tryptophan infusion.” Gillman, P. K., J. R. Bartlett, P. K. Bridges, et al. (1980). Neuropharmacology 19(12): 1241-1242

“Substances related to 5-hydroxytryptamine in plasma and in lumbar and ventricular fluids of psychiatric patients.” Curzon, G., B. D. Kantamaneni, P. Van Boxel, et al. (1980). Acta Psychiatrica Scandinavica 280: 3-20

“Decreased conjugated tyramine output in depression: the effect of oral L-cysteine.” Carter, S. M., B. L. Goodwin, M. Sandler, et al. (1980). British Journal of Clinical Pharmacology 10(3): 305-308

Share This Page

Consider Donating to PsychoTropical

PsychoTropical is funded solely through generous donations, which has enabled extensive development and improvement of all associated activities. Many people who follow the advice on the website will save enormously on doctors, treatment costs, hospitalization, etc. which in some cases will amount to many thousands of dollars, even tens of thousands — never mind all the reduction in suffering and the resultant destruction of family, work, social, and leisure capability. A donation of $100, or $500, is little compared to those savings. Some less-advantaged people feel that the little they can give is so small it won’t make a difference – but five dollars monthly helps: so, do not think that a little donation is not useful.

– Dr Ken Gillman

Dr Ken Gillman